Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

SLDB Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Solid Biosciences Inc.NASDAQ: SLDB

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 27.3% from a year ago

Common stock stood at $98K at the end of Q1 FY2026, up 27.3% from a year earlier and up 24.1% from the prior quarter. Over 3 fiscal years it compounded at +58.1% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +27.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$98K+24.1% QoQ
Last fiscal yearDec 2025
$79K+97.5% YoY
Year agoMar 2025
$77K+27.3% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.3%——
1 year+97.5%——
3-year CAGR+58.1%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
79K USD
Year-over-year change
+97.5%
4-year CAGR
+83.3%

Common Stock vs competitors

How SLDB compares with its peers on the latest reported figures

  • SLDB's Mar 2026 common stock of $98K is the highest of the 10 companies compared; the peer median is $10K.
  • Its year-over-year change of +27.3% is the 3rd highest of 9, against a peer median of +7.6%.
  • Common stock amounts to 0.0% of total assets for SLDB, versus a peer median of 0.0%.
SLDB Competitors Peer median
Common Stock for SLDB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SLDBSolid Biosciences Inc.Mar 2026$98K +27.3%+58.1%0.0%
PTCTPTC Therapeutics, Inc.Jun 2026$82K +5.1%+3.6%0.0%
CAPRCapricor Therapeutics, Inc.Mar 2026$57.67K +26.2%+31.5%0.0%
DYNDyne Therapeutics, Inc.Jun 2026$16K +45.5%+38.7%0.0%
SRPTSarepta Therapeutics, Inc.Mar 2026$11K +10.0%+6.9%0.0%
EWTXEdgewise Therapeutics, Inc.Sep 2026$10K +0.0%+18.6%0.0%
PEPGPepGen Inc.Mar 2026$7K +133.3%+51.8%0.0%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$5K +0.0%+26.0%0.0%
MGTXMeiraGTx Holdings plcMar 2026$3K +0.0%+14.5%0.0%
NGNENeurogene Inc.Mar 2026$0 ——0.0%
Peer median (excluding SLDB) $10K+7.6%+22.3%0.0%

Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents119.14M155.38M74.02M80.24M59.9M
Short-term Investments88.64M58.34M49.63M68.69M127.95M
Net Receivables110K0000
Inventory00000
Other Current Assets8.71M3M2.11M1.65M17.61M
Total Current Assets222.61M219.64M129.73M157.3M205.46M
Property, Plant & Equipment (Net)7.6M38.61M33.16M29.04M26.09M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2.16M2.01M2.04M2.32M991K
Total Non-current Assets9.77M40.61M35.21M31.36M27.08M
Total Assets232.38M260.25M164.94M188.66M232.54M
Account Payables4.46M3.24M2.03M4.24M3.22M
Short-term Debt00002.1M
Tax Payables00000
Deferred Revenue8.08M0000
Other Current Liabilities3.12M8.38M5.95M9.37M28.15M
Total Current Liabilities23.6M22.51M14.52M30.26M33.47M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities096K000
Total Non-current Liabilities568K26.08M23.94M21.16M19.06M
Total Liabilities24.17M48.59M38.46M51.42M52.53M
Common Stock7K20K20K40K79K
Retained Earnings(476.76M)(562.74M)(658.75M)(783.45M)(957.78M)
Accumulated OCI(45K)(68K)15K47K52K
Other Stockholders Equity00000
Minority Interest00000
Total Equity208.21M211.67M126.48M137.25M180.01M
Total Debt2.06M28.55M26.27M24.18M21.16M
Net Debt(117.07M)(126.84M)(47.75M)(56.06M)(38.74M)

Solid Biosciences Inc.

NASDAQ:SLDB

Intrinsic Alpha fair value

Locked

Current Price

$6.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.